Andere talen ExpreS2ion Biotech Holding AB

Aandelen

EXPRS2

SE0008348262

Beurs gesloten - Nasdaq Stockholm Andere beurzen 17:29:50 10-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,47 ^SEK	-0,68%		+1,10%	-30,33%

16/04	ExpreS2ion kondigt de voltooiing aan van het GLP-veiligheidsonderzoek voor ES2B-C001 (HER2-VLP) kandidaat-vaccin tegen borstkanker	CI
21/02	JV van ExpreS2ion Biotech ontvangt 10 miljoen euro na voltooiing van COVID-19-vaccinstudie door Bavarian Nordic	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

ExpreS2ion Biotech : Annual report 2023 including Auditor’s report	08/05
ExpreS2ion annual report for 2023 published	08/05
Notice to attend the Annual General Meeting in ExpreS2ion Biotech Holding AB (publ)	03/05
ExpreS2ion announces a rights issue of units of approximately SEK 60 million	02/05
ExpreS2ion to receive approximately SEK 22.5 million dividend payment from AdaptVac ApS	23/04
ExpreS2ion changes dates for the annual general meeting and the publication of the annual report for 2023	16/04
ExpreS2ion announces completion of GLP safety study for ES2B-C001 (HER2-VLP) breast cancer vaccine candidate	16/04
ExpreS2ion Announces Completion of GLP Safety Study for ES2B-C001 (HER2-VLP) Breast Cancer Vaccine Candidate	16/04
ExpreS2ion to present in investor and R&D events in March	15/04
ExpreS2ion to present in investor and R&D events in March	29/02
ExpreS2ion Biotech JV Secures EUR10 Million Following Bavarian Nordic's Completion of COVID-19 Vaccine Trial	21/02
ExpreS2ion's Associated Company AdaptVac Receives Milestone Payment Following Completion of Bavarian Nordic's Clinical Phase III Study for the COVID-19 Vaccine	21/02
ExpreS2ion announces financial results for the fourth quarter and full-year 2023	08/02
ExpreS2ion to present in Redeye Fight Cancer event and the Bio Innovation Leaders Summit	22/01
ExpreS2ion to present new Nipah virus vaccine project in upcoming webcast	12/12
Pareto Securities publishes research report	04/12
ExpreS2ion Biotech Unit Secures EUR8 Million Grant for Virus Vaccine Project; Shares Soar	01/12
ExpreS2ion announces new EU-funded Horizon Europe grant award for Nipah virus vaccine development	01/12
ExpreS2ion CEO interviewed, CFO provides update at life science investor conference, Analysguiden publishes research report	27/11
ExpreS2ion announces financial results for the third quarter 2023	16/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen ExpreS2ion Biotech Holding AB

Aandelen

EXPRS2

SE0008348262

Andere talen

Filters